AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03610945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305
Description: Subjects will receive a single dose of EDP-305 on Day 1 and Day 8
Study NCT02082457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP10811 5mg
Study NCT02082457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP10811 20mg
Study NCT02082457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YKP10811 placebo
Study NCT02082457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP10811 placebo
Study NCT03627559 — intervention group
Intervention type: PROCEDURE
Intervention: Pancreaticoduodenectomy microdialysis catheter analyses
Description: A thin microdialysis catheter is implanted before skin closure after pancreaticoduodenectomy. Analyses of the microdialysate are done at certain timepoints postoperatively. No intervention is done based on the results. The patients are following standard of care.
Study NCT04690907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Written material on healthy diet during pregnancy and 2 virtual dietary counseling sessions.
Study NCT02024269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose Derived Stem Cells
Study NCT00309699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily for 3 weeks
Study NCT00309699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: 400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
Study NCT00309699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 3 to 12 mg daily, flexibly dosed, for 12 weeks
Study NCT00683917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 25 mg
Description: Proellex 25 mg, 1 capsule daily for 4 months
Study NCT00683917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 50 mg
Description: Proellex 50 mg, 2 capsules daily for 4 months
Study NCT00683917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron Depot
Description: Lupron 3.75 mg monthly intramuscular injections for 4 months
Study NCT01175434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School-Based Medication Delivery
Description: For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
Study NCT02425982 — intervention group
Intervention type: PROCEDURE
Intervention: Operative treatment
Description: The exact treatment depends on the surgeon, but the majority are anticipated to be elbow arthroscopy followed by either arthroscopic or open extensor carpi radialis brevis release.
Study NCT02425982 — intervention group
Intervention type: PROCEDURE
Intervention: Conservative treatment
Description: The treatment consists of physiotherapy, activity modification, pain medication and watchful waiting. Injection therapies will be avoided.
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Multimodal analgesic regimen to Group A and Group B
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Multimodal analgesic regimen to Group A and Group B
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Multimodal analgesic regimen to Group A and Group B
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Multimodal analgesic regimen to Group A and Group B
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Multimodal analgesic regimen to Group A and Group B
Study NCT04170504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qing Re Huo Xue (QRHX) granule
Description: Qing Re Huo Xue (QRHX) granule 10g bid for 24 weeks
Study NCT04170504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral methotrexate 10 mg per week for 24 weeks.
Study NCT04170504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral methotrexate 10 mg per week for 24 weeks.
Study NCT04170504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qing Re Huo Xue (QRHX) granule placebo
Description: Qing Re Huo Xue (QRHX) granule placebo 10g bid for 24 weeks
Study NCT02823574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02823574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00255372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 4000 (Forlax®)
Description: Powder for oral solution. 2 sachets of 4g, from baseline every two weeks over a 4 week treatment period.
Study NCT00255372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose active and Lactulose placebo
Description: Powder for oral solution. 1 sachet of 3.3g lactulose active and 1 sachet of lactulose placebo. From baseline every two weeks over a 4 week treatment period.
Study NCT01925144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT01925144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally
Study NCT03769818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Bilateral TAP block with 20 ml of 0.25% bupivacaine
Study NCT03769818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Bilateral TAP block with 4 mg/kg dexamethasone diluted with isotonic saline.
Study NCT03769818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to dexamethasone
Description: Bilateral TAP block with placebo to dexamethasone.
Study NCT03769818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to dexamethasone
Description: Bilateral TAP block with placebo to dexamethasone.
Study NCT03769818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to bupivacaine
Description: Bilateral TAP block with placebo to bupivacaine.
Study NCT03009708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Two blood tubes will be collected each week during 8 weeks maximum for the present study. Samples will start at day 30 post-graft and finish at day 90 post-graft maximum.
Study NCT02432274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Cohort 1: Lenvatinib will be administered orally, once daily on Days 1 to 28 of each 28-day cycle at a starting dose of 11 mg/m2. Dose can be de-escalated to 9 mg/m2 or escalated to 14 and 17 mg/m2.
Study NCT02432274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Cohort 2A: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Multimodal analgesic regimen to Group A and Group B
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Multimodal analgesic regimen to Group A and Group B
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Multimodal analgesic regimen to Group A and Group B
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Multimodal analgesic regimen to Group A and Group B
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Multimodal analgesic regimen to Group A and Group B
Study NCT02987920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Multimodal analgesic regimen to Group A and Group B
Study NCT02432274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Cohort 2B: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
Study NCT02432274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Cohort 3A: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at 20% lower than RD determined in Cohort 1 (starting dose). Lenvatinib dose can be escalated to the RD from Cohort 1 or de-escalated to 40 and 60% lower than the RD from Cohort 1.
Study NCT02432274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Cohort 3B: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at the RD as determined in Cohort 3A.
Study NCT02432274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 3000 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Ifosfamide dose can be de-escalated to 2400 mg/m2/day and 1800 mg/m2/day.
Study NCT02432274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Etoposide dose can be de-escalated to 80 mg/m2/day and 60 mg/m2/day.
Study NCT02432274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
Study NCT02432274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
Study NCT01717066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the ginsenoside Rg3
Study NCT01717066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01209195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: increasing doses of MM-121 IV QW
Study NCT01209195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel - 80 mg/m2 IV QW
Study NCT03057600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: standard weekly paclitaxel in 28-day cycles
Study NCT03057600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: CB-839 administered as oral tablets twice daily (BID)
Study NCT02767674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IVD day0
Study NCT02767674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 IVD day0
Study NCT02767674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1 g/m2 IVD day 1
Study NCT02767674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/m2 IVD day1
Study NCT02767674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 400 mg/m2 IVD d1
Study NCT02767674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin Injectable Product
Description: Epirubicin 35 mg/m2 IVD d1
Study NCT02767674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vindesine
Description: Vindesine 2 mg IVP d1
Study NCT02767674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 40mg/m2 PO d1-5
Study NCT03396107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 6mg, IM, 48 hours before cesarean section
Study NCT03396107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 6mg, IM, 48 hours before cesarean section
Study NCT05558072 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Toll-like receptor 4
Description: Toll-like receptor 4
Study NCT03497052 — intervention group
Intervention type: OTHER
Intervention: In vitro culture in medium 1
Description: Oocytes and embryos will be cultured in GEMS media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
Study NCT03497052 — intervention group
Intervention type: OTHER
Intervention: In vitro culture in medium 2
Description: Oocytes will be cultured in IRVINE media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
Study NCT03411382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit muscle strength training
Description: Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
Study NCT03411382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game training
Description: Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
Study NCT03411382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sitting strength + game training
Description: Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
Study NCT03411382 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health education
Description: Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
Study NCT03418545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM VOLBELLA® XC injectable gel
Description: JUVÉDERM® VOLBELLA™ XC dermal filler injected into the infraorbital and adjacent area.
Study NCT02167451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Study NCT01935063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Couple Therapy
Description: CBCT includes the following: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of sexual functioning, reduce sexual distress and increase sexual satisfaction; (5) consolidate skills.
Study NCT01935063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical Lidocaine
Description: Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (2003). In addition, the cream will be applied to a cotton ball kept on the vestibule via the participant's underwear overnight to ensure a continued 7 to 8-hour contact between the anesthetic and the vestibule. A pamphlet with figures detailing how to apply the cream will be given to participants, in addition to a calibrated measurement tool to ensure that all participants apply the same quantity every night.
Study NCT00198419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitrase
Study NCT01116206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: 2 mg tablet, orally once daily, for 12 weeks
Study NCT01116206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet, orally once dailyfor 12 weeks
Study NCT01218659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat hydrochloride
Description: 150-mg capsule administered orally QOD
Study NCT01218659 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: agalsidase
Description: Agalsidase via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information
Study NCT01632956 — intervention group
Intervention type: BEHAVIORAL
Intervention: in-person support group
Description: Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
Study NCT02890446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: upper arm training on the InMotion 2 shoulder robot
Description: Both groups practiced shoulder and elbow exercises on a robotic arm device under an external focus or internal focus practice condition.~Practiced arm reaching in a clock-like design to facilitate horizontal shoulder flexion, extension, abduction, adduction.~12 sessions--3 times a week for 4 weeks
Study NCT02707250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tap Block performed with normal sterile saline 20 ml on the right side and 20 ml on the left side
Study NCT02707250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Tap Block performed with Bupivacaine 0,25% 20 ml on the right side and 20 ml on the left side.
Study NCT02707250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: Tap Block performed with pethidine 1% 10 ml on the right side and 10 ml on the left side
Study NCT02707250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine Local Infiltration (L.I)
Description: Local infiltration of port sites (trocar insertion sites) with pethidine 1% 5ml each port (trocar site) ,4 ports total 20 ml pethidine 1%
Study NCT02031666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-56021927 capsule
Description: Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.
Study NCT02031666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 tablet
Description: Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
Study NCT03342196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Alkylating agent which is a derivative of mechlorethamine that inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA; acts on both resting and rapidly dividing tumor cells.~Melphalan may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash.
Study NCT03342196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.~Thiotepa may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash.
Study NCT03342196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is an antineoplastic fluorinated nucleoside analog and inhibits DNA synthesis through inhibition of polymoerase alpha after incorporation into DNA.~Fludarabine may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash, and lower limb weakness.
Study NCT05801068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor Xa Inhibitor
Description: Hold and resume factor Xa inhibitor during perioperative/periprocedural period according to the predefined protocol.
Study NCT03242174 — intervention group
Intervention type: OTHER
Intervention: Health Behavior Questionnaire Packet
Description: Any pregnant woman offered the questionnaire at her prenatal appointment in the third trimester can complete
Study NCT04668872 — intervention group
Intervention type: RADIATION
Intervention: Y90 TARE
Description: Y90 TARE will be performed as standard of care (SOC)/clinically indicated: 1) in a lobar or sub-lobar fashion (depending on tumor involvement and location; also targeting the tumor as selective as possible and sparing as much as possible of non-involved liver parenchyma), for participants with extensive bilobar disease or 2) in a radiation segmentectomy approach, intending to deliver 190 Gy radiation dose to target tumor: for patients with limited liver metastatic disease, not amenable for surgery or ablation.